melanotan articles ↓

Clinuvel has announced today that Italy has pre-empted the approval of Afamelanotide by the FDA in the US by approving it for the treatment of erythropoietic protoporphyria (EPP).

Despite the relatively small number of participants in the Italian trial to treat EPP, and the small number of EPP sufferers …

There is a lot of interest amongst rosacea sufferers surrounding the possibility of some kind of systemic treatment that will offer better UV protection. Especially for those with severe triggers from sun exposure, treatments like Afamelanotide look promising. The CEO and Director of Clinuvel, Dr Philippe Wolgen, was kind enough to answer some questions relating to their developments and any potential tie-in with …

A blog posting at Clinuvel interviews a family struggling with the severe disease Erythropoietic Protoporphyria. Parents Wendy and Ralph talk about the distress and anguish at seeing their young children suffer the pain of EPP. Also known as absolution light intolerance, Erythropoietic Protoporphyria (EPP) is caused by a build up of protoporphyrin in the skin. Exposure to the sun causes these molecules to …

Clinuvel is announcing more positive results with its trial of the melanin boosting drug afamelanotide for the disease polymorphic light eruption (PLE). Even though this condition is rare and it is a stretch to say that treating rosacea with this drug is a given, it is still interesting to follow the development of this drug. Today’s press release relate to the continuing …

Clinuvel has  announced positive interim Phase III results from the first of the trialists to complete a 12 month study in Switzerland. The 14 patients in Switzerland will form part of 101 to undergo long term study around the world. Further participants and …